-
2023.11.09SanegeneBio and Huadong Medicine Collaborate to Develop Novel siRNA Drugs for the Treatment of Chronic Metabolic DiseasesMore
-
2023.10.07SanegeneBio first RNAi drug was approved for clinical trial in ChinaMore
-
2023.05.31Sanegene Announces Dosing of the First Subject in Phase I Trial of SGB-3403 Targeting PCSK9 for the Treatment of HypercholesterolemiaSanegene completed dosing of the first subject in Phase I trial of SGB-3403 in Australia. SGB-3403 is our first siRNA drug, targeting PCSK9 for the treatment of hypercholesterolemia, demonstrating we have entered the clinical stage.More
-
2023.05.29Sanegene Bio was awarded "Technological SMEs"More
-
2023.05.19Dr. Weimin Wang, President of Sanegene Bio, was awarded "Sci-tech Entrepreneur of 36kr"More
-
2023.01.06SanegeneBio and Orbit Discovery Collaborate to Identify Targeting Peptides for RNAi DrugsSanegene Bio USA Inc., (SanegeneBio) and Orbit Discovery Limited (Orbit) has signed a Master Service Agreement. The focus of the collaboration is to identify tissue-specific delivery of a wide range of RNA therapeutics to efficiently knock down disease-causing genes.More
-
2022.07.18Suzhou SanegeneBio will move into Phase III of BioBAYOn July18, 2022, Zone B, Phase III of Suzhou BioBAY officially opened, attracting 21 biopharmaceutical companies to settle in.More
